Patent · US Active

EBV vaccine

US11097003B2 · kind B2 · utility

1Cited by

2References

13Claims

0Family size

Assignee

Deutsches Krebsforschungszentrum · DE

Inventors

Henri-Jacques Delecluse · Heidelberg, DE
Anatoliy Shumilov · Heidelberg, DE
Ming-Han Tsai · Hsinchu, TW

Key dates

Filing date	Nov 10, 2017
Grant date	Aug 24, 2021
Priority date	—
Expiry date	Nov 10, 2037

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2710/16234
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to a composition comprising Epstein-Barr Virus (EBV) particles for use in vaccination of a subject, wherein said EBV particles comprise a significantly reduced chromosome instability-inducing EBV polypeptide activity. The present invention also relates to a composition comprising EBV particles for use in vaccination of a subject, wherein said vaccination comprises avoiding contacting the cytosol and/or nucleus of cells of said subject with a chromosome instability-inducing EBV polypeptide activity. Moreover, the present invention relates to polynucleotides, host cells, methods, and uses related to the aforesaid compositions.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.